title: Clinical feature of men who benefit from dose escalation of naftopidil for lower urinary tract symptoms: a prospective study.
abstract: Objectives. To examine the feature of men who benefit from dose escalation of naftopidil for lower urinary tract symptoms (LUTSs). Methods. Based on the IPSS, men reporting LUTS were prospectively studied using 50 mg/day of naftopidil for the first 4 weeks; satisfied patients continued its 50 mg/day (n = 11), and those reporting unsatisfactory improvement received its 75 mg/day (n = 35) for the next 4 weeks. Results. The 75 mg group showed improvement in the total IPSS and QOL score in a dose-dependent manner (at 4 weeks: P < .001, at 4 weeks versus 8 weeks: P < .05). In the 50 mg group, both scores reduced at 4 weeks, thereafter unchanged. The baseline slow stream score alone was higher in the 75 mg group (P = .013). The rate of change in the QOL score during the initial 4 weeks (ΔQOL) and Δnocturia was smaller in the 75 mg group (P < .05). Conclusions. Men with high slow stream score and unsatisfactory improvement in nocturia may benefit from dose escalation of naftopidil.
authors: Division of Urology, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Asahimachi 1, Niigata 951-8510, Japan.
authors: Takaki
authors: T
authors: Mizusawa
authors: Noboru
authors: N
authors: Hara
authors: Kenji
authors: K
authors: Obara
authors: Etsuko
authors: E
authors: Isahaya
authors: Yuki
authors: Y
authors: Nakagawa
authors: Kota
authors: K
authors: Takahashi
references: BJU Int. 2003 Sep;92(4):409-14
references: 12930430
references: Urology. 1998 Mar;51(3):428-36
references: 9510348
references: Br J Pharmacol. 2006 Feb;147 Suppl 2:S88-119
references: 16465187
references: Urology. 2006 Sep;68(3):560-4
references: 16979726
references: J Urol. 2006 Jan;175(1):358-64
references: 16406942
references: Prostate. 1994 Jul;25(1):46-52
references: 7517541
references: Neurourol Urodyn. 2002;21(2):167-78
references: 11857671
references: BMJ. 1994 Apr 9;308(6934):929-30
references: 8173393
references: J Urol. 2007 Apr;177(4):1385-9
references: 17382738
references: World J Urol. 2011 Apr;29(2):225-31
references: 20309563
references: Jpn J Pharmacol. 1999 Apr;79(4):447-54
references: 10361884
references: Int J Urol. 2001 Apr;8(4):177-83
references: 11260350
references: Int J Urol. 2008 Mar;15(3):193-9
references: 18304211
references: Pharmacoeconomics. 1999 Apr;15(4):369-76
references: 10537955
references: Int J Urol. 2010 Jun;17(6):555-62
references: 20370847
references: J Urol. 2005 Jul;174(1):370-4
references: 15947692
references: Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5
references: 17049716
references: J Urol. 2002 Mar;167(3):1513-21
references: 11832780
references: BJU Int. 2006 Apr;97(4):747-51, discussion 751
references: 16536766